Research Feed Live
New papers today
1,847
↑ 12% vs last week
Active trials
480K+
↑ 3 new this week
Cross-disease signals
92
↑ 8 identified this week
Disorders tracked
214
Updated daily
All disorders
ALS
Parkinson's
MS
Alzheimer's
Epilepsy
Clinical Trials ClinicalTrials.gov
All phases
Recruiting
Phase III
Phase II
Data sourced from ClinicalTrials.gov. Outcome language is factual per trial sponsor reports. Historical pattern scores are derived from analogous completed trials — not forecasts of any trial's outcome. Research use only.
Relationship Map
Disease
Mechanism
Drug
Biomarker
Trial
Institution
Click any node to explore
The relationship map shows 62 connections between diseases, mechanisms, drugs, trials, and institutions. Click any node to see what it connects to.
Research signals — trial activity patterns Evidence-based
Trial activity patterns by mechanism class
Antisense / gene silencing
84%
Remyelination (SM-452 class)
79%
Glymphatic modulation
61%
Anti-tau monoclonal antibody
48%
Anti-amyloid monoclonal antibody
37%
% = proportion of analogous completed trials that met primary endpoint · Pattern score · CI ±9% · Not a forecast
Pathway research activity — 10-year trend Observational
Neuroinflammation / Microglia
+92%
Glymphatic clearance
+78%
Gene silencing / RNA therapy
+67%
Tau targeting
+54%
Remyelination
+43%
Increase in pathway-specific research activity (papers + trial enrollment) over 5 years. Observational trend data — not a forecast of clinical outcomes.
Research Pathways Expert reviewed · AI-assisted
ALS
Parkinson's
MS
Alzheimer's
Epilepsy
Research pathway maps represent AI interpretation of the published scientific landscape. They may not reflect current expert consensus. Verify with primary literature. Not clinical guidance.
Research Links AI-identified · Evidence-backed
✦ AI has identified cross-disease research connection opportunities below. All connections display supporting evidence. Confidence tiers indicate level of validation. Verify with primary literature before acting on any connection.